<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604589</url>
  </required_header>
  <id_info>
    <org_study_id>2015-233</org_study_id>
    <nct_id>NCT02604589</nct_id>
  </id_info>
  <brief_title>Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures</brief_title>
  <official_title>Prime &quot;Rib&quot; Time: Randomized Control Trial Evaluating the Use of Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthony Iacco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rib fractures are common injuries in accident patients and can be associated with significant
      pain during recovery. If poorly controlled, pain from splinting due to rib fractures can
      result in difficulty in breathing leading to incomplete expansion of lung, and even the need
      to put a patient on a ventilator to help them breathe. Therefore, pain control is critical in
      managing patients with rib fractures. To date, many studies have shown the effectiveness of
      continuous intercostal nerve blockade (a slow release of pain medications at the site of
      injury that prevents the transmission of pain signals). This approach has never been studied
      in a randomized fashion in rib fracture patients, and has never been compared to
      patient-controlled narcotic pain medication, commonly used at many hospitals. The purpose of
      this study is to evaluate the effectiveness of the placement of an elastomeric infusion pump
      (a small, external, wearable balloon used to deliver medication over time) attached to a
      continuous infusion catheter or &quot;soaker&quot; catheter (a tube which releases the pain medication
      through tiny holes in it, right at the site of injury) to deliver local anesthetic medication
      to reduce pain caused by two or more rib fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of rib fractures using an elastomeric infusion pump (a small, external, wearable
      balloon used to deliver medication over time) containing pain medication and a continuous
      infusion catheter or &quot;soaker&quot; catheter (a tube which releases the pain medication through
      tiny holes in it, right at the site of injury) placed in the extrathoracic paraspinous space
      (a site in the back that is near the broken ribs) to create a continuous intercostal nerve
      block is relatively novel. Truitt and colleagues have published two studies evaluating the
      effectiveness of this approach. A pilot study on 30 patients was published in 2010 showing
      that placement of these catheters was a safe, viable and effective procedure, and resulted in
      decreased pain scores in rib fracture patients. A second study included 102 patients studied
      prospectively (from the time of admission to the hospital) comparing epidural anesthesia (an
      injection of anesthetic into the spine) with local catheter delivery in a non-randomized
      fashion in 2011. This approach is beginning to be more widely used, but has never been
      studied in a randomized fashion, and has never been compared to patient-controlled analgesia
      (PCA, delivery of a pain medication by the push of a button), commonly used at many
      hospitals.

      We hypothesize that accident patients with two or more rib fractures who receive pain control
      through the continuous infusion system will achieve improved pain control in a dose-dependent
      fashion, improved lung function, and therefore, will require less narcotic pain medication,
      achieve discharge criteria earlier and have a shorter hospital length of stay in comparison
      to patients treated with PCA alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    resource reallocation
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Narcotic Use</measure>
    <time_frame>3 days or hospital length of stay, if less than 3 days</time_frame>
    <description>Quantity of systemic narcotic used (hydromorphone hydrochloride, Dilaudid) averaged per day over the length of hospital stay, in mg/24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in Pulmonary Function</measure>
    <time_frame>3 days or hospital length of stay, if less than 3 days</time_frame>
    <description>Determine the impact of catheter-infused medications on maximal inspiratory lung volume measured by incentive spirometer (IS) as a change from baseline at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group). Endpoint will be the time to improvement of vital capacity to greater than 1.4 liters (or 15 mL/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in Pain Intensity</measure>
    <time_frame>3 days or hospital length of stay, if less than 3 days</time_frame>
    <description>Determine the impact of catheter-infused medications on self-reported pain intensity reported as a change from baseline (admission) at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group) on a 0-10 point Likert scale, with 0=no pain, and 10= the worst pain ever. Response will be defined as time to a decrease of at least two points on the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>3 days or hospital length of stay, whichever is longer</time_frame>
    <description>Collection of complications observed at any point during the hospital admission that included randomization, including pneumothorax, hemothorax, acute respiratory distress syndrome, pneumonia, empyema, need for tracheostomy, need for mechanical ventilation, length of time on mechanical ventilation, and an assessment of the degree of association of each event with the catheter insertion procedure or with underlying trauma. Each of these outcomes will be scored as yes/no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All cause death, death associated with infusion catheter, within 30 days from date of randomization. This outcome will be scored as yes/no and cause of death will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>from randomization to discharge, usually within the range of 5-15 days</time_frame>
    <description>Integer days of inpatient admission in the hospital stay that included randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Intensive Care Unit (SICU) Length of Stay</measure>
    <time_frame>from admission to Surgical Intensive Care unit to discharge from Surgical Intensive Care Unit</time_frame>
    <description>Integer days of admission to the surgical intensive care unit. For patients not requiring admission to surgical intensive care, patient is not analyzed. Usual range is 3-5 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Rib Fractures</condition>
  <arm_group>
    <arm_group_label>PCA only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivicaine 0.25% (LOW DOSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivicaine 0.5% (HIGH DOSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydromorphone hydrochloride</intervention_name>
    <description>Patient-controlled narcotic analgesia pump</description>
    <arm_group_label>PCA only</arm_group_label>
    <arm_group_label>Bupivicaine 0.25% (LOW DOSE)</arm_group_label>
    <arm_group_label>Bupivicaine 0.5% (HIGH DOSE)</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infusion catheter placement</intervention_name>
    <description>Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space</description>
    <arm_group_label>Bupivicaine 0.25% (LOW DOSE)</arm_group_label>
    <arm_group_label>Bupivicaine 0.5% (HIGH DOSE)</arm_group_label>
    <other_name>OnQ pump placement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivicaine 0.25%</intervention_name>
    <description>Low Dose analgesia</description>
    <arm_group_label>Bupivicaine 0.25% (LOW DOSE)</arm_group_label>
    <other_name>Marciane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivicaine 0.5%</intervention_name>
    <description>High dose analgesia</description>
    <arm_group_label>Bupivicaine 0.5% (HIGH DOSE)</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to trauma service at Beaumont Hospital, Royal Oak, Michigan

          -  Two or more rib fractures in an anatomic pattern feasible for nerve blockade
             (unilateral or bilateral)

          -  Age greater than or equal to 18 years

          -  Ability to comprehend and endorse an informed consent

        Exclusion Criteria:

          -  Patients who are pregnant or breastfeeding

          -  Patients intubated before placement of continuous infusion catheter

          -  Any significant concomitant injuries potentially confounding for evaluation of the
             effectiveness of analgesia (eg., traumatic brain injury)

          -  History of an allergic reaction to local anesthetic

          -  Use of other regional anesthetics before evaluation (epidural or paravertebral nerve
             blockade)

          -  International Normalized Ratio (INR) &gt; 2.0

          -  Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Iacco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaumont Hospital, Royal Oak MI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.beaumont.edu/</url>
    <description>Beaumont Health System</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <results_first_submitted>January 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Anthony Iacco</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Catheters, Indwelling</keyword>
  <keyword>Infusion Pumps</keyword>
  <keyword>Anesthesia, Local</keyword>
  <keyword>Analgesia, Patient-Controlled</keyword>
  <keyword>Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCA Only</title>
          <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
        </group>
        <group group_id="P2">
          <title>Bupivicaine 0.25% (LOW DOSE)</title>
          <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
        </group>
        <group group_id="P3">
          <title>Bupivicaine 0.5% (HIGH DOSE)</title>
          <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>catheter dislodgement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCA Only</title>
          <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
        </group>
        <group group_id="B2">
          <title>Bupivicaine 0.25% (LOW DOSE)</title>
          <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
        </group>
        <group group_id="B3">
          <title>Bupivicaine 0.5% (HIGH DOSE)</title>
          <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.67" spread="16.56"/>
                    <measurement group_id="B2" value="60.40" spread="24.93"/>
                    <measurement group_id="B3" value="63.50" spread="6.36"/>
                    <measurement group_id="B4" value="61.40" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Ribs Fractured</title>
          <units>ribs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="2.5"/>
                    <measurement group_id="B2" value="6.6" spread="3.7"/>
                    <measurement group_id="B3" value="5.0" spread="1.4"/>
                    <measurement group_id="B4" value="5.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission Incentive Spirometry (IS) Volume</title>
          <description>Maximal inspiratory lung volume measured by incentive spirometer (IS)</description>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="978" spread="563"/>
                    <measurement group_id="B2" value="783" spread="630"/>
                    <measurement group_id="B3" value="1567" spread="818"/>
                    <measurement group_id="B4" value="998" spread="696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission Pain Score</title>
          <description>Analog pain scale of 1-10, where 1= no pain and 10= worst pain ever</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="8" upper_limit="8"/>
                    <measurement group_id="B2" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B3" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B4" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Narcotic Use</title>
        <description>Quantity of systemic narcotic used (hydromorphone hydrochloride, Dilaudid) averaged per day over the length of hospital stay, in mg/24 hours.</description>
        <time_frame>3 days or hospital length of stay, if less than 3 days</time_frame>
        <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Use</title>
          <description>Quantity of systemic narcotic used (hydromorphone hydrochloride, Dilaudid) averaged per day over the length of hospital stay, in mg/24 hours.</description>
          <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group</population>
          <units>mg/24 hours over days 1-3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="3.5"/>
                    <measurement group_id="O2" value="8.2" spread="5.16"/>
                    <measurement group_id="O3" value="2.5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement in Pulmonary Function</title>
        <description>Determine the impact of catheter-infused medications on maximal inspiratory lung volume measured by incentive spirometer (IS) as a change from baseline at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group). Endpoint will be the time to improvement of vital capacity to greater than 1.4 liters (or 15 mL/kg).</description>
        <time_frame>3 days or hospital length of stay, if less than 3 days</time_frame>
        <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group. This leaves only one member to analyze; therefore standard deviation = 0.</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in Pulmonary Function</title>
          <description>Determine the impact of catheter-infused medications on maximal inspiratory lung volume measured by incentive spirometer (IS) as a change from baseline at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group). Endpoint will be the time to improvement of vital capacity to greater than 1.4 liters (or 15 mL/kg).</description>
          <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group. This leaves only one member to analyze; therefore standard deviation = 0.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.5"/>
                    <measurement group_id="O2" value="1.8" spread="1.6"/>
                    <measurement group_id="O3" value="1.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement in Pain Intensity</title>
        <description>Determine the impact of catheter-infused medications on self-reported pain intensity reported as a change from baseline (admission) at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group) on a 0-10 point Likert scale, with 0=no pain, and 10= the worst pain ever. Response will be defined as time to a decrease of at least two points on the scale.</description>
        <time_frame>3 days or hospital length of stay, if less than 3 days</time_frame>
        <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group. Only one subject remains to be analyzed in that group so standard deviation = 0</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in Pain Intensity</title>
          <description>Determine the impact of catheter-infused medications on self-reported pain intensity reported as a change from baseline (admission) at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group) on a 0-10 point Likert scale, with 0=no pain, and 10= the worst pain ever. Response will be defined as time to a decrease of at least two points on the scale.</description>
          <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group. Only one subject remains to be analyzed in that group so standard deviation = 0</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0"/>
                    <measurement group_id="O2" value="3.0" spread="0"/>
                    <measurement group_id="O3" value="1.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morbidity</title>
        <description>Collection of complications observed at any point during the hospital admission that included randomization, including pneumothorax, hemothorax, acute respiratory distress syndrome, pneumonia, empyema, need for tracheostomy, need for mechanical ventilation, length of time on mechanical ventilation, and an assessment of the degree of association of each event with the catheter insertion procedure or with underlying trauma. Each of these outcomes will be scored as yes/no.</description>
        <time_frame>3 days or hospital length of stay, whichever is longer</time_frame>
        <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidity</title>
          <description>Collection of complications observed at any point during the hospital admission that included randomization, including pneumothorax, hemothorax, acute respiratory distress syndrome, pneumonia, empyema, need for tracheostomy, need for mechanical ventilation, length of time on mechanical ventilation, and an assessment of the degree of association of each event with the catheter insertion procedure or with underlying trauma. Each of these outcomes will be scored as yes/no.</description>
          <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group</population>
          <units>number of complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>All cause death, death associated with infusion catheter, within 30 days from date of randomization. This outcome will be scored as yes/no and cause of death will be collected.</description>
        <time_frame>30 days</time_frame>
        <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>All cause death, death associated with infusion catheter, within 30 days from date of randomization. This outcome will be scored as yes/no and cause of death will be collected.</description>
          <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Integer days of inpatient admission in the hospital stay that included randomization.</description>
        <time_frame>from randomization to discharge, usually within the range of 5-15 days</time_frame>
        <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group. This leaves only one subject to analyze, so standard deviation =0</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Integer days of inpatient admission in the hospital stay that included randomization.</description>
          <population>One subject withdrawn in Bupivicaine 0.5% (HIGH DOSE) group. This leaves only one subject to analyze, so standard deviation =0</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="2.1"/>
                    <measurement group_id="O2" value="11.1" spread="8.6"/>
                    <measurement group_id="O3" value="3.6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Intensive Care Unit (SICU) Length of Stay</title>
        <description>Integer days of admission to the surgical intensive care unit. For patients not requiring admission to surgical intensive care, patient is not analyzed. Usual range is 3-5 days.</description>
        <time_frame>from admission to Surgical Intensive Care unit to discharge from Surgical Intensive Care Unit</time_frame>
        <population>Only patients analyzed who had surgical intensive care unit admission.</population>
        <group_list>
          <group group_id="O1">
            <title>PCA Only</title>
            <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
          </group>
          <group group_id="O2">
            <title>Bupivicaine 0.25% (LOW DOSE)</title>
            <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
          </group>
          <group group_id="O3">
            <title>Bupivicaine 0.5% (HIGH DOSE)</title>
            <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Intensive Care Unit (SICU) Length of Stay</title>
          <description>Integer days of admission to the surgical intensive care unit. For patients not requiring admission to surgical intensive care, patient is not analyzed. Usual range is 3-5 days.</description>
          <population>Only patients analyzed who had surgical intensive care unit admission.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0"/>
                    <measurement group_id="O2" value="5.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from enrollment through the first 3 days of hospitalization.</time_frame>
      <desc>An assessment of medical records and case report forms were examined for Adverse Events or Serious Adverse Events. Reports were reviewed by the PI for accuracy and relation to study intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>PCA Only</title>
          <description>Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.</description>
        </group>
        <group group_id="E2">
          <title>Bupivicaine 0.25% (LOW DOSE)</title>
          <description>bupivicaine 0.25%: Low Dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.</description>
        </group>
        <group group_id="E3">
          <title>Bupivicaine 0.5% (HIGH DOSE)</title>
          <description>bupivicaine 0.5%: High dose analgesia
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
PLUS Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>No source vocabulary</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Low urine output</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to lack of enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rose Callahan</name_or_title>
      <organization>William Beaumont Hospital</organization>
      <phone>248 551-5147</phone>
      <email>rose.callahan@beaumont.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

